Invivyd Q2 loss per share comes wider than expected on higher costs

Invivyd

13/08/2026 21:25

Overview
U.S. biopharma firm's Q2 PEMGARDA revenue rose 21% yr/yr on higher patient demand
Q2 net loss per share missed analyst expectations
Company ended Q2 with $160.1 mln in cash, supporting ongoing clinical trial programs

Outlook
Company expects top-line data from DECLARATION and LIBERTY trials in late Q3 2026
Invivyd anticipates cash runway through DECLARATION pivotal data readout and potential VYD2311 launch readiness
PEMGARDA emergency use authorization expected to terminate June 29, 2027; company in dialogue with FDA on next steps

Result Drivers
PATIENT DEMAND - Co said 21% yr/yr PEMGARDA revenue growth was driven by increased patient demand
CLINICAL TRIAL COSTS - Higher R&D expenses were primarily due to increased contract research costs for DECLARATION and LIBERTY clinical trials
COMMERCIAL AND PERSONNEL EXPENSES - SG&A expenses increased due to higher personnel, communications and commercial-related costs

Company press release: ID:nGNX3N406Y

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$14.29 mln
 
Q2 Loss Per Share
Miss
$0.14
$0.11 (3 Analysts)
Q2 Net Loss
Miss
$44.39 mln
$26.98 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Invivyd, Inc. is $10.00, about 1,266.1% above its August 12 closing price of $0.73

Reuters Recommended Reads
Aug 13 - Ovid Therapeutics Q2 revenue beats estimates 
Aug 13 - Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Aug 12 - Aprea Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)